Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-β type I receptor inhibitors

被引:169
作者
Gellibert, FO
Woolven, J
Fouchet, MH
Mathews, N
Goodland, H
Lovegrove, V
Laroze, A
Nguyen, VL
Sautet, S
Wang, RL
Janson, C
Smith, W
Krysa, G
Boullay, V
de Gouville, AC
Huet, S
Hartley, D
机构
[1] GlaxoSmithKline, Dept Med Chem, F-91951 Les Ulis, France
[2] GlaxoSmithKline, Dept Biol, F-91951 Les Ulis, France
[3] GlaxoSmithKline, Discovery Res, Computat & Struct Sci, Stevenage SG1 2NY, Herts, England
[4] GlaxoSmithKline, Dept Med Chem, Stevenage SG1 2NY, Herts, England
[5] GlaxoSmithKline, Discovery Res, Assay Dev & Compound Profiling, Res Triangle Pk, NC 27709 USA
[6] GlaxoSmithKline, Discovery Res, King Of Prussia, PA 19406 USA
关键词
D O I
10.1021/jm0400247
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Optimization of the screening hit 1 led to the identification of novel 1,5-naphthyridine aminothiazole and pyrazole derivatives, which are potent and selective inhibitors of the transforming growth factor-beta type I receptor, ALK5. Compounds 15 and 19, which inhibited ALK5 autophosphorylation with IC50 = 6 and 4 nM, respectively, showed potent activities in both binding and cellular assays and exhibited selectivity over p38 mitogen-activated protein kinase. The X-ray crystal structure of 19 in complex with human ALK5 is described, confirming the binding mode proposed from docking studies.
引用
收藏
页码:4494 / 4506
页数:13
相关论文
共 28 条